Embryonic stem cell therapy-Parkinson's Disease - BresaGen
Latest Information Update: 28 May 2007
At a glance
- Originator BresaGen
- Mechanism of Action Dopaminergic cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 04 Feb 2004 The directors of BresaGen have resigned and administrators have been appointed
- 08 May 2003 Preclinical trials in Parkinson's disease in Australia (Intracranial)